[go: up one dir, main page]

WO2004078186A1 - Ointment preparation for repairing injured skin - Google Patents

Ointment preparation for repairing injured skin Download PDF

Info

Publication number
WO2004078186A1
WO2004078186A1 PCT/JP2004/002625 JP2004002625W WO2004078186A1 WO 2004078186 A1 WO2004078186 A1 WO 2004078186A1 JP 2004002625 W JP2004002625 W JP 2004002625W WO 2004078186 A1 WO2004078186 A1 WO 2004078186A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight
preparation
ointment
sucrose
consistency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2004/002625
Other languages
French (fr)
Japanese (ja)
Inventor
Masahiro Nishimura
Takahito Kimura
Takahiko Aoki
Kenji Aso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Teika Pharamaceutical Co Ltd
Original Assignee
Kowa Co Ltd
Teika Pharamaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd, Teika Pharamaceutical Co Ltd filed Critical Kowa Co Ltd
Priority to JP2005503064A priority Critical patent/JP4398425B2/en
Publication of WO2004078186A1 publication Critical patent/WO2004078186A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/18Iodine; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • A61K31/787Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A61K31/79Polymers of vinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Definitions

  • the present invention keeps the iodine content constant, and furthermore has excellent spreadability and flexibility.
  • the present invention relates to an ointment preparation for repairing damaged skin containing sucrose and povidonodo, whose consistency is hardly changed with time. Fine
  • saccharides have been known to have a granulation-proliferating action and a bacteriostatic action, and povidonodo is a drug commonly used as a fungicide.
  • a preparation containing an alkali metal alginate Japanese Patent Application Laid-Open No. 11-100023
  • urea carboxyvinyl polymer, hyaluronic acid Or a salt-containing preparation
  • JP-A-10-338638 a non-aqueous preparation
  • JP-A-2002-241287 a preparation containing a solubilizing agent and a shape retaining agent selected from polysaccharides
  • No. 09-40563 have been proposed, but none of them have been described as solving stability problems, such as not mentioning stability or poor stability.
  • the present invention has been made in view of the above, and provides an ointment preparation for repairing damaged skin containing sucrose and povidone chloride which stably retains the iodine content and has excellent spreadability and flexibility. As an issue.
  • the present inventors have conducted intensive studies and as a result, by using xanthone gum and / or cyclodextrin as a base component, the formulation has the required spreadability and flexibility, The present inventors have found that an ointment preparation for repairing damaged skin containing sucrose and povidonide stably retaining a high iodine content can be obtained, and the present invention has been completed.
  • the present invention comprises 50 to 90% by weight of sucrose, 0.5 to 10% by weight of povidone, 0.1 to 20% by weight of water, and 0.01 to 2% by weight of xanthan gum and / or cyclodextrin.
  • An ointment preparation for repairing damaged skin characterized in that To provide.
  • an ointment preparation for repairing wounded skin containing sucrose and povidonide which has a constant iodine content, is excellent in spreadability and flexibility, and whose consistency is hardly changed with time. be able to.
  • sucrose in the present invention purified sucrose described in the Japanese Pharmacopoeia is preferable, and its content is usually 50 to 90% by weight, preferably 60 to 80% by weight based on the total amount of the preparation from the viewpoint of therapeutic effect. And particularly preferably 70% by weight.
  • the povidonide listed in the Japanese Pharmacopoeia it is preferable to use the povidonide listed in the Japanese Pharmacopoeia, and its content is usually 0-5 to 10% by weight, preferably from 5 to 10% by weight, preferably from the viewpoint of therapeutic effect.
  • the content is 1 to 7% by weight, particularly preferably 2 to 6% by weight.
  • purified water listed in the Japanese Pharmacopoeia as the water in the present invention, and its content is usually 0.1 to 20% by weight, preferably 0.3 to 15% by weight based on the total amount of the preparation. %, Particularly preferably 0.5 to 12% by weight. It is.
  • the xanthan gum in the present invention is a polysaccharide in which D-glucose, D-mannose, and D-dalc lanic acid are mainly linked in a chain, and specific commercial products include eco-gum (Dainippon Pharmaceutical, Sanshin), Neosoft (Kohjin), Soaxane (Mitsubishi Rayon), Kuchiichi Digel (Rhone Poulin Japan), Xanthan Gum (San-Ei Gen FFF I, Takeda Pharmaceutical).
  • the content of the xanthan gum should be less than the solubility in water, since the xanthan gum dissolves in water and exerts a thickening effect to obtain an iodine content stabilizing effect and a consistency stabilizing effect. However, it is usually 0.01 to 1% by weight, preferably 0.02 to 0.5% by weight, particularly preferably 0.05 to 0.3% by weight, based on the total amount of the preparation.
  • the cyclodextrin used in the present invention has a large number of D-dalcopyranos groups.
  • Specific commercial products include Celdex (Nippon Shokuhin Kako) and Lindex-1B (Mershan) , I3-cyclodextrin (Hayashibara) and the like.
  • the cyclodextrin includes ⁇ -cyclodextrin, ⁇ -cyclodextrin, and ⁇ -cyclodextrin, and ⁇ -cyclodextrin is particularly preferred.
  • the content of the cyclodextrin is usually from 0.01 to 1% by weight, preferably from 0.02 to 0.5% by weight, particularly preferably from 0.02 to 0.5% by weight, based on the iodine content and the effect of stabilizing the consistency. Is from 0.05 to 0.2% by weight.
  • Xansu gum and cyclodextrin may be used alone, but it is particularly preferable to use them in combination from the viewpoint of the effect of stabilizing the iodine content and the consistency.
  • Their content is usually from 0.01 to 2% by weight, preferably from 0.02 to 0.5% by weight, particularly preferably from 0.05 to 0.5% by weight, based on the total amount of the preparation. Since the ointment preparation for repairing damaged skin of the present invention is in the form of an ointment, it can be easily applied to a skin ulcer such as a pressure ulcer, a burn ulcer, and a leg ulcer to treat it.
  • the ointment state means that the consistency (25 ° C.) measured using a texture analyzer is 1 to 900 g, particularly preferably 1 to 500 g.
  • the consistency was measured using a texture analyzer after filling 30 g in a standard bottle (No. 5), storing at 25 ° C-60% RH for 1 hour, and measuring with a texture analyzer. This is the stress (g) when the metal ball adapter was inserted into the formulation at a penetration speed of 60 min Zmin.
  • the pH of the preparation of the present invention is preferably in the range of 3.5 to 6.
  • the pH can be measured, for example, by scraping 1 g of an ointment preparation for repairing damaged skin, adding 9 g of water, shaking well, and measuring with a pH meter (H-24, F-24).
  • various optional components that are acceptable as pharmaceutical additives can be added to the preparation of the present invention as desired.
  • the optional components include a solubilizer, Examples include a surfactant, a thickener, and a pH adjuster.
  • Solubilizing agents include potassium iodide, sodium iodide, glycerin, 1,3-butylene glycol, polyethylene glycol 200, polyethylene glycol 400, polyethylene dalicol 150, polyethylene glycol 400 0, polyethylene glycol 600, polypropylene glycol, propylene glycol and the like.
  • surfactant examples include polyoxyethylene lauryl alcohol ester, polyoxyethylene polyoxypropylene glycol, polyoxyethylene hydrogenated castor oil, and the like.
  • thickeners in addition to xanthan gum, ester gum, arabic gum, carrageenan, tamarind seed gum, guar gum, tragacanth gum, force-doran, dielan gum, pectin, polyisobutylene, pullulan, sodium carboxymethylcellulose, Sodium alginate, methylcellulose, agar, gelatin and the like may be added.
  • Examples of the pH adjuster include sodium hydroxide, citric acid, and acetic acid.
  • the ointment preparation for repairing damaged skin of the present invention can be produced, for example, by mixing the above-mentioned raw materials and stirring until the mixture becomes uniform.
  • Purified water 8.64 g, concentrated glycerin 1.0 g, polyethylene glycol 400 14.19 g, polyoxyethylene [160] polyoxypropylene [30] glycol 1.3 g, potassium iodide 0.7 g, citrate 0.3 lg, 8 mol ZL aqueous sodium hydroxide solution 0.31 g, povidonodo 3.0 g, purified sucrose 70.0 g, polyoxyethylene (9) lauryl alcohol ester 0.5 g, xanthate gum 0.06 g, 3-cyclodextrin 0.2 g
  • the iodine content in the ointment preparation for wound skin repair (iodine content immediately after production) was set to 100%).
  • the measurement was performed by precisely weighing about 5 g of an ointment preparation for wound skin repair, adding 40 g of purified water, stirring and dissolving, and using a 1 mol / L sodium thiosulfate solution, a Hiranuma automatic titrator (Hiranuma Sangyo Co., Ltd.) Company: Performed by titration with C0MTITE-900). The results are shown in Table 1.
  • Example 3 After storage, the consistency of Example 3 was 36.3 g after storage and the consistency of Comparative Example was 120 g. As shown in Table 1, the comparative example in which xanthan gum was not used had a remarkably high consistency and was not usable.
  • Example 1 in which xansan gum was added at 0.06 g, 0.15 g, and 0.30 g, respectively, the consistency was greatly improved. Further, in Example 4 in which 0.2 g of 3-cyclodextrin was further added to the method of Example 1, the stability and consistency of the iodine content were further improved as compared with Examples 1, 2 and 3. The stability of sucrose was also good. Therefore, satisfactory results were obtained in all aspects of spreadability, flexibility and stability of the active ingredient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

It is intended to provide an ointment preparation for repairing injured skin containing sucrose and Popidon Yodo which sustains iodine at a stable constant and is excellent in spreadability and flexibility. An ointment preparation for repairing injured skin which contains from 50 to 90% by weight of sucrose, from 0.5 to 10% by weight of Popidon Yodo, from 0.1 to 20% by weight of water and from 0.01 to 2% by weight of xanthan gum and/or cyclodextrin.

Description

損傷皮膚修復用軟膏状製剤  Ointment preparation for repairing damaged skin

技術分野 Technical field

本発明は、 ヨウ素含量を一定に保持し、 さらに展延性及び柔軟性に優れ、 その 明  The present invention keeps the iodine content constant, and furthermore has excellent spreadability and flexibility.

稠度が経時的に変化しにくい、 白糖とポビドンョードを含有する損傷皮膚修復用 軟膏状製剤に関する。 細 The present invention relates to an ointment preparation for repairing damaged skin containing sucrose and povidonodo, whose consistency is hardly changed with time. Fine

背景技術 Background art

従来より、 糖類は肉芽増殖作用及び静菌作用を有することが知られており、 ま た、 ポビドンョードは殺菌剤として一般的に繁用されている薬剤である。 これら Hitherto, saccharides have been known to have a granulation-proliferating action and a bacteriostatic action, and povidonodo is a drug commonly used as a fungicide. these

2つの薬剤、 グラニュー糖とポビドンョ一ド製剤を混合して種々の損傷皮膚に塗 布したところ、 優れた皮膚修復効果が得られたことが既に報告されている (病院 薬学、 第 1 0巻 3 1 5— 3 2 2 ( 1 9 8 4 ) ) 。 また、 糖 5 0〜9 0重量%、 ポビドンョ一ド 0 . 5〜1 0重量%、 水 1〜2 0重量%及び製剤の pHを 3 . 5〜 6に調整する緩衝剤を含有する損傷皮膚修復製剤 (特公平 1一 3 2 2 1 0号公 報) も報告されており、 実際臨床の場で使用され高い治療効果を挙げている。 しかし、 糖類を含有する軟膏状製剤は調製後経時的に稠度が増すという問題点 があった。 稠度が増加すると使用感が悪化するばかりでなく、 傷部分への均一な 塗布が困難となる。 糖類含有軟膏状製剤の稠度を下げる製剤処方的解決方法とし ては、 糖類の配合量を減少させたり、 水の配合量を増加させたりする方法がある が、 いずれの方法も製剤に分離が生じたり、 表面に分離した成分による斑点が出 現するなど安定性に問題があつた。 It has already been reported that an excellent skin repair effect was obtained when two drugs, granulated sugar and povidonide preparation, were mixed and applied to various types of damaged skin (Hospital Pharmacy, Vol. 10, No. 3). 1 5—3 2 2 (1 9 8 4)). In addition, damaged skin containing 50 to 90% by weight of sugar, 0.5 to 10% by weight of water, 1 to 20% by weight of water, and a buffer for adjusting the pH of the preparation to 3.5 to 6 Restorative preparations have also been reported (Japanese Patent Publication No. Hei 11-32210), and have been used in clinical practice and have high therapeutic effects. However, ointment-like preparations containing saccharides have a problem that the consistency increases over time after preparation. Increasing the consistency not only deteriorates the usability, but also makes it difficult to apply evenly to the wound. Solutions to reduce the consistency of saccharide-containing ointment formulations include reducing the amount of saccharides and increasing the amount of water, but all of these methods result in separation of the formulation. In addition, there were problems with stability, such as the appearance of spots due to components separated on the surface.

この問題を解決するために、 アルギン酸アルカリ金属塩を加えた製剤 (特開平 1 1 - 1 0 0 3 2 3号公報) 、 尿素、 カルボキシビ二ルポリマー、 ヒアルロン酸 又はその塩を加えた製剤 (特開平 10— 338638号公報) 、 非水系の製剤 (特開 2002— 241287号公報) 、 可溶化剤 ·多糖類から選ばれる保型剤 を加えた製剤 (特開平 09— 40563号公報) が提案されているが、 これらは いずれも安定性に触れていないか、 又は安定性が悪いなど、 安定性の問題を解決 しているとは言えないものである。 In order to solve this problem, a preparation containing an alkali metal alginate (Japanese Patent Application Laid-Open No. 11-100023), urea, carboxyvinyl polymer, hyaluronic acid Or a salt-containing preparation (JP-A-10-338638), a non-aqueous preparation (JP-A-2002-241287), a preparation containing a solubilizing agent and a shape retaining agent selected from polysaccharides (JP-A-Hei 10-338638). No. 09-40563) have been proposed, but none of them have been described as solving stability problems, such as not mentioning stability or poor stability.

また、 製剤中に気泡を含ませて稠度を下げる方法も報告されている (特開 2002-193810号公報) が、 工程数の増加や特別な設備が必要になるな ど、 コスト面で課題を残している。 以上のように、 従来糖類を含有する軟膏状製 剤は、 経時的に稠度が増したり、 安定性に問題が起こったりすることがあった。 従って、 いつまでも柔らかく異物感のない、 かつ安定な製剤が期待されていた。 一方、 糖類及びョードホールを含有する成形体からなる創傷治療用製剤も報告 されている (特開 2002-226381号公報) が、 軟膏に比べ取り扱いやす いという利点がある反面、 深い創傷には適用しづらいという欠点がある。 発明の開示  In addition, a method has been reported to reduce the consistency by including air bubbles in the formulation (Japanese Patent Application Laid-Open No. 2002-193810), but there are problems in terms of cost, such as an increase in the number of steps and the need for special equipment. Have left. As described above, the conventional ointment-form preparations containing saccharides may increase in consistency with time or have a problem in stability. Therefore, a stable formulation that is soft and free of foreign body sensation has been expected. On the other hand, a wound treatment formulation comprising a molded product containing saccharides and odor holes has also been reported (Japanese Patent Application Laid-Open No. 2002-226381). There is a disadvantage that it is difficult. Disclosure of the invention

本発明は、 上記観点からなされたものであり、 ヨウ素含量を安定的に保持し、 さらに展延性、 柔軟性に優れた白糖とポビドンョ一ドを含有する損傷皮膚修復用 軟膏状製剤を提供することを課題とする。  The present invention has been made in view of the above, and provides an ointment preparation for repairing damaged skin containing sucrose and povidone chloride which stably retains the iodine content and has excellent spreadability and flexibility. As an issue.

以上のような現状において、 本発明者らは、 鋭意検討を行った結果、 基剤成分 としてキサン夕ンガム及び/又はシクロデキストリンを用いることにより、 製剤 に求められる展延性、 柔軟性を具備し、 力 ^つ高いヨウ素含量を安定的に保持した 白糖とポビドンョ一ドを含有する損傷皮膚修復用軟膏状製剤が得られることを見 出し、 本発明を完成するに至った。  Under the current situation as described above, the present inventors have conducted intensive studies and as a result, by using xanthone gum and / or cyclodextrin as a base component, the formulation has the required spreadability and flexibility, The present inventors have found that an ointment preparation for repairing damaged skin containing sucrose and povidonide stably retaining a high iodine content can be obtained, and the present invention has been completed.

すなわち、 本発明は、 白糖 50〜90重量%、 ポビドンョード 0. 5〜10重 量%、 水 0. 1〜20重量%並びにキサンタンガム及び/又はシクロデキストリ ン 0. 01〜 2重量%を含有することを特徴とする損傷皮膚修復用軟膏状製剤を 提供するものである。 That is, the present invention comprises 50 to 90% by weight of sucrose, 0.5 to 10% by weight of povidone, 0.1 to 20% by weight of water, and 0.01 to 2% by weight of xanthan gum and / or cyclodextrin. An ointment preparation for repairing damaged skin, characterized in that To provide.

本発明により、 ヨウ素含量を一定に保持し、 さらに展延性及び柔軟性に優れ、 その稠度が経時的に変化しにくい、 白糖とポビドンョ一ドを含有する創傷皮膚修 復用軟膏状製剤を提供することができる。 発明を実施するための最良の形態  According to the present invention, there is provided an ointment preparation for repairing wounded skin containing sucrose and povidonide, which has a constant iodine content, is excellent in spreadability and flexibility, and whose consistency is hardly changed with time. be able to. BEST MODE FOR CARRYING OUT THE INVENTION

以下に本発明を詳細に説明する。  Hereinafter, the present invention will be described in detail.

本発明における白糖としては日本薬局方収載の精製白糖が好ましく、 その含有 量は、 治療効果の点から製剤全量に対して通常 5 0〜 9 0重量%で、 好ましくは 6 0〜8 0重量%であり、 特に好ましくは 7 0重量%である。  As the sucrose in the present invention, purified sucrose described in the Japanese Pharmacopoeia is preferable, and its content is usually 50 to 90% by weight, preferably 60 to 80% by weight based on the total amount of the preparation from the viewpoint of therapeutic effect. And particularly preferably 70% by weight.

本発明におけるポビドンョ一ドも日本薬局方収載のものを使用するのが好まし く、 その含有量は、 治療効果の点から製剤全量に対して通常 0 - 5〜1 0重量% で、 好ましくは 1〜7重量%であり、 特に好ましくは 2〜 6重量%である。 本発明における水も日本薬局方収載の精製水を使用するのが好ましく、 その含 有量は、 製剤全量に対して通常 0 . 1〜2 0重量%で、 好ましくは 0 . 3〜1 5 重量%であり、 特に好ましくは 0 . 5〜1 2重量。である。  In the present invention, it is preferable to use the povidonide listed in the Japanese Pharmacopoeia, and its content is usually 0-5 to 10% by weight, preferably from 5 to 10% by weight, preferably from the viewpoint of therapeutic effect. The content is 1 to 7% by weight, particularly preferably 2 to 6% by weight. It is preferable to use purified water listed in the Japanese Pharmacopoeia as the water in the present invention, and its content is usually 0.1 to 20% by weight, preferably 0.3 to 15% by weight based on the total amount of the preparation. %, Particularly preferably 0.5 to 12% by weight. It is.

本発明におけるキサンタンガムとは、 主に D—グルコースと D—マンノース、 D一ダルク口ン酸が鎖状に結合した多糖類であり、 具体的な市販品としてはェコ —ガム (大日本製薬、 三晶) 、 ネオソフト (興人) 、 ソアキサン (三菱レイョ ン) 、 口一ディゲル (ローヌプーラン ·ジャパン) 、 キサンタンガム (三栄源ェ フ ·エフ ·アイ、 武田薬品工業) などが挙げられる。 当該キサンタンガムの含有 量は、 キサン夕ンガムが水に溶解して増粘作用を発揮させてヨウ素含量安定化効 果及び稠度安定化効果を得る点から、 水に対する溶解度以下の量である必要があ るが、 製剤全量に対して通常 0 . 0 1〜 1重量%で、 好ましくは 0 . 0 2〜 0 . 5重量%、 特に好ましくは 0 . 0 5〜0 . 3重量%である。  The xanthan gum in the present invention is a polysaccharide in which D-glucose, D-mannose, and D-dalc lanic acid are mainly linked in a chain, and specific commercial products include eco-gum (Dainippon Pharmaceutical, Sanshin), Neosoft (Kohjin), Soaxane (Mitsubishi Rayon), Kuchiichi Digel (Rhone Poulin Japan), Xanthan Gum (San-Ei Gen FFF I, Takeda Pharmaceutical). The content of the xanthan gum should be less than the solubility in water, since the xanthan gum dissolves in water and exerts a thickening effect to obtain an iodine content stabilizing effect and a consistency stabilizing effect. However, it is usually 0.01 to 1% by weight, preferably 0.02 to 0.5% by weight, particularly preferably 0.05 to 0.3% by weight, based on the total amount of the preparation.

本発明に用いるシクロデキストリンとは、 多数の D—ダルコピラノ一ス基が ο; 1→4グリコシド結合によって環化した構造をもつ、 結晶性に優れた一連のオリ ゴ糖同族体であり、 具体的な市販品としてはセルデックス (日本食品化工) 、 リ ンデックス一 B (メルシャン) 、 i3—シクロデキストリン (林原) などが挙げら れる。 また、 シクロデキストリンには、 α—シクロデキストリン、 β—シクロデ キストリン、 Ύ—シクロデキストリンがあるが、 β—シクロデキストリンが特に 好ましい。 当該シクロデキストリンの含有量は、 ヨウ素含量及び稠度の安定化効 果の点から、 製剤全量に対して通常 0. 01〜1重量%で、 好ましくは 0. 02 〜0. 5重量%、 特に好ましくは 0. 05〜0. 2重量%である。 The cyclodextrin used in the present invention has a large number of D-dalcopyranos groups. A series of homologous oligosaccharides with excellent crystallinity, having a structure cyclized by 1 → 4 glycosidic bonds. Specific commercial products include Celdex (Nippon Shokuhin Kako) and Lindex-1B (Mershan) , I3-cyclodextrin (Hayashibara) and the like. Further, the cyclodextrin includes α-cyclodextrin, β-cyclodextrin, and Ύ-cyclodextrin, and β-cyclodextrin is particularly preferred. The content of the cyclodextrin is usually from 0.01 to 1% by weight, preferably from 0.02 to 0.5% by weight, particularly preferably from 0.02 to 0.5% by weight, based on the iodine content and the effect of stabilizing the consistency. Is from 0.05 to 0.2% by weight.

キサン夕ンガムとシクロデキストリンはそれぞれ単独で使用してもよいが、 こ れらを併用するのがヨウ素含量及び稠度の安定化効果の点から特に好ましい。 こ れらの含有量は製剤全量に対して通常 0. 0 1〜2重量%で、 好ましくは 0. 02〜0. 5重量%、 特に好ましくは 0. 05〜0. 5重量%である。 本発明の損傷皮膚修復用軟膏状製剤は、 軟膏状であることにより、 褥瘡、 熱傷 潰瘍、 下腿潰瘍等の皮膚潰瘍の患部に容易に塗布して治療することができる。 こ こで、 軟膏状とは、 テクスチャ一アナライザ一を用いて測定した稠度 (25°C) が 1〜900 gであることをいい、 特に 1〜500 gであるのが好ましい。 ここ でいぅ稠度は、 規格ビン (No. 5) に 30 g充填し、 25°C- 60 %RHで 1 曰間保存後、 テクスチャ一アナライザ一を用いて測定したものであり、 直径 10 腿の金属球アダプターが侵入速度 60醒 Zminで製剤中へ 2 Omni挿入したときの 応力 (g) である。  Xansu gum and cyclodextrin may be used alone, but it is particularly preferable to use them in combination from the viewpoint of the effect of stabilizing the iodine content and the consistency. Their content is usually from 0.01 to 2% by weight, preferably from 0.02 to 0.5% by weight, particularly preferably from 0.05 to 0.5% by weight, based on the total amount of the preparation. Since the ointment preparation for repairing damaged skin of the present invention is in the form of an ointment, it can be easily applied to a skin ulcer such as a pressure ulcer, a burn ulcer, and a leg ulcer to treat it. Here, the ointment state means that the consistency (25 ° C.) measured using a texture analyzer is 1 to 900 g, particularly preferably 1 to 500 g. Here, the consistency was measured using a texture analyzer after filling 30 g in a standard bottle (No. 5), storing at 25 ° C-60% RH for 1 hour, and measuring with a texture analyzer. This is the stress (g) when the metal ball adapter was inserted into the formulation at a penetration speed of 60 min Zmin.

本発明製剤の PHは 3. 5〜 6の範囲が好ましい。 pHの測定は、 例えば、 損傷皮 膚修復用軟膏状製剤 1 gをかき取り水 9 gを加えてよく振り混ぜた後、 pHメータ 一 (堀場製作所: F—24) で測定することができる。  The pH of the preparation of the present invention is preferably in the range of 3.5 to 6. The pH can be measured, for example, by scraping 1 g of an ointment preparation for repairing damaged skin, adding 9 g of water, shaking well, and measuring with a pH meter (H-24, F-24).

本発明の製剤には、 本発明の効果を妨げない限り、 医薬品の添加物として許容 される各種任意成分を所望に応じて添加することが可能であり、 任意成分として は例えば、 可溶化剤、 界面活性剤、 増粘剤、 pH調整剤等が挙げられる。 可溶化剤としては、 ヨウ化カリウム、 ヨウ化ナトリウム、 グリセリン、 1, 3 ーブチレングリコ一ル、 ポリエチレングリコ一ル 2 0 0、 ポリエチレングリコー ル 4 0 0、 ポリエチレンダリコール 1 5 0 0、 ポリエチレングリコール 4 0 0 0、 ポリエチレングリコール 6 0 0 0、 ポリプロピレングリコ一ル、 プロ ピレングリコール等が挙げられる。 As long as the effects of the present invention are not impaired, various optional components that are acceptable as pharmaceutical additives can be added to the preparation of the present invention as desired. Examples of the optional components include a solubilizer, Examples include a surfactant, a thickener, and a pH adjuster. Solubilizing agents include potassium iodide, sodium iodide, glycerin, 1,3-butylene glycol, polyethylene glycol 200, polyethylene glycol 400, polyethylene dalicol 150, polyethylene glycol 400 0, polyethylene glycol 600, polypropylene glycol, propylene glycol and the like.

界面活性剤としては、 ポリオキシエチレンラウリルアルコールエステル、 ポリ ォキシエチレンポリオキシプロピレングリコ一ル、 ポリオキシェチレン硬化ヒマ シ油等が挙げられる。  Examples of the surfactant include polyoxyethylene lauryl alcohol ester, polyoxyethylene polyoxypropylene glycol, polyoxyethylene hydrogenated castor oil, and the like.

増粘剤としては、 キサンタンガムの他、 エステルガム、 アラビアガム、 カラギ 一ナン、 タマリンドシードガム、 グァ一ガム、 トラガントガム、 力一ドラン、 ジ エランガム、 ぺクチン、 ポリイソプチレン、 プルラン、 カルボキシメチルセル口 ースナトリウム、 アルギン酸ナトリウム、 メチルセルロース、 寒天、 ゼラチン等 を配合しても良い。 '  As thickeners, in addition to xanthan gum, ester gum, arabic gum, carrageenan, tamarind seed gum, guar gum, tragacanth gum, force-doran, dielan gum, pectin, polyisobutylene, pullulan, sodium carboxymethylcellulose, Sodium alginate, methylcellulose, agar, gelatin and the like may be added. '

pH調整剤としては、 水酸化ナトリウム、 クェン酸、 酢酸等が挙げられる。 本発明の損傷皮膚修復用軟膏状製剤は、 例えば、 上記の原料を混合し、 均一に なるまで撹拌することにより、 製造することができる。 実施例  Examples of the pH adjuster include sodium hydroxide, citric acid, and acetic acid. The ointment preparation for repairing damaged skin of the present invention can be produced, for example, by mixing the above-mentioned raw materials and stirring until the mixture becomes uniform. Example

以下に実施例を用いて本発明を具体的に説明する。  Hereinafter, the present invention will be specifically described with reference to Examples.

各実施例は、 精製水と濃ダリセリンの混合溶液に、 ヨウ化カリウム、 クェン 酸、 水酸化ナトリウム、 ポビドンョ一ド、 キサンタンガム (実施例 1〜 4の み) 、 /3—シクロデキストリン (実施例 4のみ) を添加、 溶解させ、 予製剤 Iと し、 一方、 ポリエチレングリコ一ル 4 0 0にポリエチレン (9 ) ラウリルアルコ ールエステル、 ポリオキシエチレン [ 1 6 0 ] ポリオキシプロピレン [ 3 0 ] グ リコールを添加、 溶解させ、 予製剤 I Iとした後、 予製剤 Iに白糖を添加し、 練合 後、 予製剤 I Iを加えて 5 ΠΜで練合を行うことにより調製した。 実施例 1 In each example, potassium iodide, citric acid, sodium hydroxide, povidone chloride, xanthan gum (only in Examples 1 to 4), / 3-cyclodextrin (Example 4) were added to a mixed solution of purified water and concentrated dariserin. Only) and dissolved to give Preformulation I, while adding polyethylene (9) lauryl alcohol ester, polyoxyethylene [160] polyoxypropylene [30] glycol to polyethylene glycol 400 After adding and dissolving to obtain Pre-formulation II, sucrose was added to Pre-formulation I, and after kneading, pre-formulation II was added and kneaded in 5 ml. Example 1

精製水 8. 84 g、 濃グリセリン 1. 0 g、 ポリエチレングリコール 400 14. 1 9 g、 ポリオキシエチレン [160] ポリオキシプロピレン [30] グ リコ一ル 1. 3 g、 ヨウ化カリウム 0. 7 g、 クェン酸 0. l g、 8mol/L水 酸化ナトリウム水溶液 0. 31 g、 ポビドンョ一ド 3. 0 g、 精製白糖 70. 0 g、 ポリオキシエチレン (9) ラウリルアルコールエステル 0. 5 g、 キサン夕 ンガム 0. 06 g  Purified water 8.84 g, concentrated glycerin 1.0 g, polyethylene glycol 400 14.19 g, polyoxyethylene [160] polyoxypropylene [30] glycol 1.3 g, potassium iodide 0.7 g, citrate 0.3 g, 8 mol / L sodium hydroxide aqueous solution 0.31 g, povidone chloride 3.0 g, purified sucrose 70.0 g, polyoxyethylene (9) lauryl alcohol ester 0.5 g, xane Evening Ngam 0.06 g

実施例 2 Example 2

精製水 8. 75 g、 濃グリセリン 1. 0 g、 ポリエチレングリコール 400 14. 19 g、 ポリオキシエチレン [160] ポリオキシプロピレン [30] グ リコ一ル 1. 3 g、 ヨウ化カリウム 0. 7 g、 クェン酸 0. l g、 8mol/L水 酸化ナトリウム水溶液 0. 31 g、 ポピドンョード 3. O g、 精製白糖 70. 0 g、 ポリオキシエチレン (9) ラウリルアルコールエステル 0. 5 g、 キサン夕 ンガム 0, 1 5 g  8.75 g of purified water, 1.0 g of concentrated glycerin, 14.19 g of polyethylene glycol 400, 1.3 g of polyoxyethylene [160] polyoxypropylene [30] glycol, 0.7 g of potassium iodide , Cunic acid 0.3 g, 8 mol / L aqueous sodium hydroxide solution 0.31 g, popidone oxide 3.O g, purified sucrose 70.0 g, polyoxyethylene (9) lauryl alcohol ester 0.5 g, xanthate gum 0 , 1 5 g

実施例 3 Example 3

精製水 8. 60 g、 濃グリセリン 1. 0 g、 ポリエチレングリコール 400 14. 19 g、 ポリオキシエチレン [160] ポリオキシプロピレン [30] グ リコール 1. 3 g、 ヨウ化カリウム 0. 7 g、 クェン酸 0. l g、 8molZL水 酸化ナトリウム水溶液 0. 31 g、 ポビドンョード 3. 0 g、 精製白糖 70. 0 g、 ポリオキシエチレン (9) ラウリルアルコールエステル 0. 5 g、 キサン夕 ンガム 0. 30 g  8.60 g of purified water, 1.0 g of concentrated glycerin, 14.19 g of polyethylene glycol 400, 1.3 g of polyoxyethylene [160] polyoxypropylene [30] glycol, 0.7 g of potassium iodide, 0.7 g Acid 0.5 g, 8 mol ZL sodium hydroxide aqueous solution 0.31 g, povidonodo 3.0 g, purified sucrose 70.0 g, polyoxyethylene (9) lauryl alcohol ester 0.5 g, xanthate gum 0.30 g

実施例 4 Example 4

精製水 8. 64g、 濃グリセリン 1. 0 g、 ポリエチレングリコール 400 14. 19 g、 ポリオキシエチレン [160] ポリオキシプロピレン [30] グ リコール 1. 3 g、 ヨウ化カリウム 0. 7 g、 クェン酸 0. l g、 8molZL水 酸化ナトリウム水溶液 0. 31 g、 ポビドンョード 3. 0 g、 精製白糖 70. 0 g、 ポリオキシエチレン (9) ラウリルアルコールエステル 0. 5 g、 キサン夕 ンガム 0. 0 6 g、 3—シクロデキストリン 0. 2 g Purified water 8.64 g, concentrated glycerin 1.0 g, polyethylene glycol 400 14.19 g, polyoxyethylene [160] polyoxypropylene [30] glycol 1.3 g, potassium iodide 0.7 g, citrate 0.3 lg, 8 mol ZL aqueous sodium hydroxide solution 0.31 g, povidonodo 3.0 g, purified sucrose 70.0 g, polyoxyethylene (9) lauryl alcohol ester 0.5 g, xanthate gum 0.06 g, 3-cyclodextrin 0.2 g

比較例 Comparative example

精製水 8. 90 g、 濃グリセリン 1. 0 g、 ポリエチレングリコール 400 14. 1 9 g、 ポリオキシエチレン [1 60] ポリオキシプロピレン [3 0] グ リコール 1. 3 g、 ヨウ化カリウム 0. 7 g、 クェン酸 0. l g、 8mol/L水 酸化ナトリウム水溶液 0. 3 1 g、 ポビドンョード 3. O g、 精製白糖 7 0. 0 g、 ポリオキシエチレン (9) ラウリルアルコールエステル 0. 5 g 試験 1 (ヨウ素含量)  Purified water 8.90 g, concentrated glycerin 1.0 g, polyethylene glycol 400 14.19 g, polyoxyethylene [160] polyoxypropylene [30] glycol 1.3 g, potassium iodide 0.7 g, citrate 0.3 g, 8 mol / L aqueous sodium hydroxide solution 0.3 1 g, povidone oxide 3. O g, purified sucrose 7 0.0 g, polyoxyethylene (9) lauryl alcohol ester 0.5 g Test 1 (Iodine content)

実施例 1〜 4及び比較例で得られた創傷皮膚修復用軟膏状製剤を 60°Cの条件 下で 7日間保存後、 創傷皮膚修復用軟膏状製剤中のヨウ素含量 (製造直後のヨウ 素含量を 1 00%とする) を測定した。 測定は、 創傷皮膚修復用軟膏状製剤約 5 gを精密に量り、 精製水 40 gを加えて撹拌溶解し、 0. 0 1mol/Lチォ硫酸 ナトリウム溶液にて、 平沼自動滴定装置 (平沼産業株式会社: C0MTITE- 900) を 用いて滴定することにより行つた。 その結果を表 1に示す。  After storing the ointment preparations for wound skin repair obtained in Examples 1 to 4 and Comparative Example at 60 ° C. for 7 days, the iodine content in the ointment preparation for wound skin repair (iodine content immediately after production) Was set to 100%). The measurement was performed by precisely weighing about 5 g of an ointment preparation for wound skin repair, adding 40 g of purified water, stirring and dissolving, and using a 1 mol / L sodium thiosulfate solution, a Hiranuma automatic titrator (Hiranuma Sangyo Co., Ltd.) Company: Performed by titration with C0MTITE-900). The results are shown in Table 1.

試験 2 (白糖含量) Test 2 (Sucrose content)

実施例 1〜4及び比較例で得られた創傷皮膚修復用軟膏状製剤を 6 0 °Cの条件 下で 7日間保存後、 創傷皮膚修復用軟膏状製剤中の精製白糖を定量した。 測定 は、 創傷皮膚修復用軟膏状製剤約 0. 3 5 gを精密に量り、 内標準液 1 0 mLと蒸 留水を加えて正確に 5 OmLとした試料溶液 (丁) 、 並びに標準溶液 (S) 1 5 Lにっき、 日本薬局方一般試験法の液体クロマトグラフにより行った。  After the ointment preparations for wound skin repair obtained in Examples 1 to 4 and Comparative Example were stored at 60 ° C for 7 days, purified sucrose in the ointment preparations for wound skin repair was quantified. The measurement was performed by accurately weighing about 0.35 g of an ointment preparation for wound skin repair, adding 10 mL of an internal standard solution and distilled water to make exactly 5 OmL, and preparing a sample solution (d) and a standard solution ( S) 15 L was measured by liquid chromatography according to the Japanese Pharmacopoeia General Test Method.

試験 3 (稠度試験) Test 3 (consistency test)

実施例 1〜4及び比較例で得られた創傷皮膚修復用軟膏状製剤を規格ピン (NO. 5) に約 30 g充填し、 60 °Cで 7日間保存後、 2 5 °Cの恒温室内で 1 日静置した後、 テクスチャーアナライザー (サンサイエンティフィック社製, サ ンレオメータ) を用いて測定を行った。 直径 1 0醒の金属球アダプタ一が侵入速度 6 0腿 Zminで製剤中へ 2 0腿揷入 したときの応力を測定した。 About 30 g of the ointment preparation for wound skin repair obtained in Examples 1 to 4 and Comparative Example was filled in a standard pin (NO.5) and stored at 60 ° C for 7 days. After one day at room temperature, measurement was performed using a texture analyzer (San Scientific, Sanrometer). The stress was measured when a metal ball adapter with a diameter of 10 was inserted into the preparation at a penetration rate of 60 thigh Zmin.

表 1  table 1

Figure imgf000009_0001
Figure imgf000009_0001

* 1: 25Π曰保存後の、 実施例 3の稠度は 36. 3 g、 比較例の稠度は 120 gであった。 表 1より、 キサンタンガムを使用しない比較例は稠度が著しく高く、 使用に耐 えない状態であった。  * 1: After storage, the consistency of Example 3 was 36.3 g after storage and the consistency of Comparative Example was 120 g. As shown in Table 1, the comparative example in which xanthan gum was not used had a remarkably high consistency and was not usable.

一方、 キサン夕ンガムをそれぞれ 0 . 0 6 g、 0 . 1 5 g、 0 . 3 0 g配合し た実施例 1、 2及び 3は稠度の点で大幅に改善されている。 また、 実施例 1の処 方に更に 3—シクロデキストリンを 0 . 2 g配合した実施例 4では、 ヨウ素含量 の安定度及び稠度が実施例 1、 2及び 3と比較してもさらに改善されており、 ま た、 白糖の安定性も良好であった。 従って、 展延性、 柔軟性の面及び有効成分の 安定性の全てに於いて満足できる結果となった。  On the other hand, in Examples 1, 2 and 3 in which xansan gum was added at 0.06 g, 0.15 g, and 0.30 g, respectively, the consistency was greatly improved. Further, in Example 4 in which 0.2 g of 3-cyclodextrin was further added to the method of Example 1, the stability and consistency of the iodine content were further improved as compared with Examples 1, 2 and 3. The stability of sucrose was also good. Therefore, satisfactory results were obtained in all aspects of spreadability, flexibility and stability of the active ingredient.

Claims

請求の範囲 The scope of the claims 1. 白糖 50〜90重量%、 ポビドンョード 0. 5〜: 10重量%、 水 0. 1 重量%を含有することを特徴とする損傷皮膚修復用軟膏状製剤。  1. An ointment preparation for repairing damaged skin, comprising 50 to 90% by weight of sucrose, 0.5 to: 10% by weight of povidone and 0.1% by weight of water.
PCT/JP2004/002625 2003-03-04 2004-03-03 Ointment preparation for repairing injured skin Ceased WO2004078186A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2005503064A JP4398425B2 (en) 2003-03-04 2004-03-03 Ointment preparation for repairing damaged skin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003056650 2003-03-04
JP2003-056650 2003-03-04

Publications (1)

Publication Number Publication Date
WO2004078186A1 true WO2004078186A1 (en) 2004-09-16

Family

ID=32958712

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2004/002625 Ceased WO2004078186A1 (en) 2003-03-04 2004-03-03 Ointment preparation for repairing injured skin

Country Status (2)

Country Link
JP (1) JP4398425B2 (en)
WO (1) WO2004078186A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101107469B1 (en) 2007-03-30 2012-01-19 인터내셔널 비지네스 머신즈 코포레이션 Providing memory consistency in an emulated processing environment
WO2014023718A1 (en) * 2012-08-07 2014-02-13 Dräger Safety AG & Co. KGaA Disinfectant containing a complex of iodine and cyclodextrin
JP2018121756A (en) * 2017-01-30 2018-08-09 東洋インキScホールディングス株式会社 Wound covering gel and method for producing the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0258761A1 (en) * 1986-09-02 1988-03-09 Kowa Company, Ltd. Wound-healing preparations
JP2002226381A (en) * 2001-01-31 2002-08-14 Mikasa Seiyaku Co Ltd Preparation for wound treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0258761A1 (en) * 1986-09-02 1988-03-09 Kowa Company, Ltd. Wound-healing preparations
JP2002226381A (en) * 2001-01-31 2002-08-14 Mikasa Seiyaku Co Ltd Preparation for wound treatment

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101107469B1 (en) 2007-03-30 2012-01-19 인터내셔널 비지네스 머신즈 코포레이션 Providing memory consistency in an emulated processing environment
WO2014023718A1 (en) * 2012-08-07 2014-02-13 Dräger Safety AG & Co. KGaA Disinfectant containing a complex of iodine and cyclodextrin
GB2517107A (en) * 2012-08-07 2015-02-11 Draeger Safety Ag & Co Kgaa Disinfectant containing a complex of iodine and cyclodextrin
GB2517107B (en) * 2012-08-07 2019-04-24 Draeger Safety Ag & Co Kgaa Disinfectant containing a complex of iodine and cyclodextrin
JP2018121756A (en) * 2017-01-30 2018-08-09 東洋インキScホールディングス株式会社 Wound covering gel and method for producing the same

Also Published As

Publication number Publication date
JPWO2004078186A1 (en) 2006-06-08
JP4398425B2 (en) 2010-01-13

Similar Documents

Publication Publication Date Title
JP2694166B2 (en) Gel forming liquid carrier composition
JP4294252B2 (en) G-rich alginate-containing composition
JPH10508833A (en) Hemorrhoid composition and method of use
EP2034956A1 (en) Compositions comprising glycosaminoglycans of low viscosity and use of said composition in therapy of chronic cystitis
KR20210099553A (en) Injectable sustained-release antibiotics
US11793752B2 (en) Aqueous gel composition and its use
JP3974431B2 (en) Alginic acid-containing composition
JP7359909B2 (en) A method for producing an oral composition, a method for improving the adhesion of an oral composition to an oral application part, and a method for improving retention of an oral composition in an oral application part.
WO2004078186A1 (en) Ointment preparation for repairing injured skin
JP2008056667A (en) Composition based on salt of hyaluronic acid for treating epithelial lesion
WO2025110951A1 (en) Azelaic acid-cyclodextrin complex based hydrogel formulations for acne treatment
JP2000038342A (en) Pharmaceutical preparation for restoring bedsore and damaged skin
JP2009096793A (en) Planoprofen-containing aqueous pharmaceutical composition
JPH0940563A (en) Composition for treating bed sore and skin ulcer
JP3472442B2 (en) Formulation for repairing damaged skin
JP2009102407A (en) G-rich alginic acid-containing composition
JP3936324B2 (en) Oral antifungal agent
JP2008517043A (en) Bioadhesive composition by release programming
JPH11100323A (en) External pharmaceutical preparation
JP7106852B2 (en) Suspension-type topical solution
JP2006348055A (en) Alginic acid-containing composition
JP2008031165A (en) Aqueous composition containing vitamin a compound
JP6029874B2 (en) Sol pharmaceutical composition containing itraconazole
TW202214267A (en) Method for treating oral mucositis and aqueous gel for the same
CN116421791A (en) A kind of lubricating composition for medical cavity and its preparation method and application

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005503064

Country of ref document: JP

122 Ep: pct application non-entry in european phase